Galderma Laboratories, L.P.
Dallas, TX Part of Nestle Purina Petcare Co
- UEI
- MNX4XY6QXEL3
- CAGE
- 00ZY4
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Partnership or Limited Liability Partnership
- NAICS codes registered in SAM.gov
- Corporate family
-
-
Nestle Purina Petcare Co
Parent
FJQPWJT5PLQ9
- Galderma Laboratories, L.P. MNX4XY6QXEL3
-
Nestle Purina Petcare Co
Parent
FJQPWJT5PLQ9
- SAM.gov registration date
- Physical address
- 2001 Ross Ave 16th Floor, Dallas, TX 75201, USA
- Website
- galderma.com
- Founded
- 1981
- Employees
- 5K-10K
- Estimated annual revenue
- $1B-$10B
- Industry
-
- Consumer Discretionary
- Consumer Durables & Apparel
- Consumer Goods
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Nemluvio 30 MG | Veterans Integrated Service Network 5 | $31,800 | |
| Nemluvio 30 MG | Veterans Integrated Service Network 5 | $16,960 | |
| Emergency nemluvio | Veterans Integrated Service Network 22 | $50,880 | |
| Nemluvio 30 MG | Veterans Integrated Service Network 5 | $31,800 | |
| Nemluvio 30 MG | Veterans Integrated Service Network 5 | $42,400 |
About Galderma Laboratories, L.P.
Galderma Laboratories, L.P., a foreign-owned pharmaceutical manufacturer headquartered in Dallas, Texas, supplies injectable pharmaceutical products to the Department of Veterans Affairs as a prime contractor exclusively through the GSA Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The company is a child entity within Nestle Purina Petcare Co and operates as a for-profit manufacturer with no SBA set-aside designations across its federal footprint.
Galderma's capability portfolio centers narrowly on branded injectable medications for VA patient care. The company supplies Nemluvio 30 mg (nemolizumab) and Nemolizumab CCP 30 mg injectable pens and injectables across multiple Veterans Integrated Service Network regions. Recent representative delivery orders include a $46,697.40 order from VISN 5 for Nemluvio 30 mg (September 2025), a $33,920 order from VISN 21 for 16 units of Nemolizumab 30 mg injectable pens (October 2025), a $31,800 order from VISN 5 for Nemluvio 30 mg (May 2026), and a $12,314.40 emergency order from VISN 9 for Nemolizumab CCP 30 mg injection (March 2025). Individual order values range from approximately $3,063 to $49,811, with delivery timelines typically measured in days to weeks reflecting the time-sensitive nature of pharmaceutical supply to federal healthcare operations.
Customer concentration sits entirely within the VA healthcare system across eight distinct Veterans Integrated Service Networks. VISN 5 dominates by award count with eight awards worth $273 thousand combined potential value, while VISN 12 anchors the potential-value ranking with three awards carrying $271.3 million in combined potential value — a substantial outlier driven by what appears to be a multi-year pharmaceutical supply arrangement. VISN 6, VISN 19, and VISN 21 round out active purchasing networks. All awards operate under the GSA Pharmaceuticals and Drugs Federal Supply Schedule with 11 task orders carrying $322 thousand combined potential value. The company holds no subcontract relationships and competes full-and-open with no set-aside designations.
Activity shows six awards in 2025 and four year-to-date in 2026, up from three per year in 2016-2017, indicating gradual growth in VA pharmaceutical supply relationships. Combined potential value across all 24 awards totals $271.8 million, though obligated dollars remain at only $440 thousand (0% of potential value), reflecting the delivery-order structure of VA pharmaceutical procurement where ceiling values are set but invoiced amounts depend on actual unit demand. The company has maintained federal contractor registration since February 2002 and operates its federal pharmaceutical supply business exclusively from Carrollton, Texas.
Contract vehicles
Quick answers
What is Galderma Laboratories, L.P.'s UEI?
Galderma Laboratories, L.P.'s Unique Entity ID (UEI) in SAM.gov is MNX4XY6QXEL3.
What is Galderma Laboratories, L.P.'s CAGE code?
Galderma Laboratories, L.P.'s CAGE code is 00ZY4.
What is Galderma Laboratories, L.P.'s primary NAICS code?
Galderma Laboratories, L.P.'s primary NAICS code is 325412 (Pharmaceutical Preparation Manufacturing).
Where is Galderma Laboratories, L.P. located?
Galderma Laboratories, L.P.'s physical address in SAM.gov is 2001 Ross Ave 16th Floor, Dallas, TX 75201, USA.
Is Galderma Laboratories, L.P. registered in SAM.gov?
Yes. Galderma Laboratories, L.P.'s SAM.gov registration is active through December 24, 2026.
Who is Galderma Laboratories, L.P.'s parent company?
Galderma Laboratories, L.P. is part of Nestle Purina Petcare Co.
Which contract vehicles does Galderma Laboratories, L.P. hold?
Galderma Laboratories, L.P. holds a place on 1 federal contract vehicle: FSS-61-IB.
What is Galderma Laboratories, L.P.'s most recent federal award?
Galderma Laboratories, L.P.'s most recent federal contract award is Nemluvio 30 MG (36C24526N0882), from Veterans Integrated Service Network 5, on September 29, 2026.
On GovTribe
See Galderma Laboratories, L.P.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors